Veradermics, Inc MANE
We are a dermatologist-founded, late clinical-stage biopharmaceutical company, or the "Company," "we," "us," or "our", focused on developing innovative therapeutics to address pervasive treatment challenges in highly prevalent aesthetic and dermatological conditions. Our initial focus is developing better treatments for PHL, a condition affecting approximately 50 million men and 30 million women in the United States. Current PHL treatment options are limited and therefore are consistently plagued with high rates of treatment failure, patient dissatisfaction and treatment discontinuation. Patients and healthcare providers routinely identify the following shortcomings with currently available treatment options:
Valuation FY2025 figures against the last close
Annual financial statements
Income statement
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| R&D | $62.1M | $23.3M | — |
| SG&A | $10.3M | $3.5M | — |
| Total operating expenses | $72.3M | $26.8M | — |
| Operating income | -$72.3M | -$26.8M | — |
| Interest expense | $0 | $585.0K | — |
| Pre-tax income | -$70.0M | -$26.5M | — |
| Income tax | $0 | $0 | — |
| Net income | -$70.0M | -$26.5M | — |
| EPS, basic | -111.91 | -37.05 | — |
| EPS, diluted | -111.91 | -37.05 | — |
| Shares, diluted (wtd. avg.) | 744,991 | 736,933 | — |
Balance sheet
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Cash and equivalents | $21.8M | $53.1M | $16.3M |
| Short-term investments | $120.1M | $0 | — |
| Total current assets | $152.5M | $55.5M | — |
| Property, plant and equipment | $22.0K | $0 | — |
| Total assets | $152.6M | $55.5M | — |
| Accounts payable | $2.1M | $2.2M | — |
| Total current liabilities | $9.2M | $4.7M | — |
| Total liabilities | $9.2M | $4.7M | — |
| Retained earnings | -$123.4M | -$49.2M | — |
| Total equity | -$121.0M | -$48.5M | -$22.2M |
Cash flow
| Fiscal year | FY2025 | FY2024 | FY2023 |
|---|---|---|---|
| Operating cash flow | -$71.6M | -$23.7M | — |
| Stock-based compensation | $1.4M | $250.0K | — |
| Capital expenditure | $24.0K | $0 | — |
| Investing cash flow | -$118.9M | $0 | — |
| Financing cash flow | $159.1M | $60.5M | — |
Figures as tagged in each year's own filing, in US dollars. A year restated by a later filing shows the restated figure. Capital expenditure, dividends and buybacks are cash out, shown positive. A line the filer does not report is not listed. Latest from accession 0001827635-26-000013.
Plot the figures US dollars
- Revenue
- Gross profit
- Net income
| Fiscal year | FY2023 | FY2024 | FY2025 |
|---|---|---|---|
| Revenue | — | — | — |
| Gross profit | — | — | — |
| Net income | — | -$26.5M | -$70.0M |
Recent filings and events
- Results announced The quarterly or annual earnings release. Arrives four times a year from almost every company here. Item 2.02
- Regulation FD disclosure Something the company told the market and had to tell everyone at once - usually a slide deck or a press release. Item 7.01
- Other event The catch-all. The company chose to disclose something that fits no other item, so the content is whatever it says it is. Item 8.01
- Results announced Item 2.02
- Material agreement signed The company entered an agreement outside the ordinary course of business - a large contract, a credit facility, a merger agreement. Item 1.01
- Unregistered share sale Shares issued outside a registered offering. Dilution, and for a small company often the way it is funded. Item 3.02
- Results announced Item 2.02
- Regulation FD disclosure Item 7.01
- Other event Item 8.01
- Annual report filed A new 10-K. The figures and the business description on this site come from it. Form 10-K
- Results announced Item 2.02
- Charter or fiscal year changed A change to the company's governing documents, or to when its year ends. Item 5.03
Item numbers are Form 8-K's own, and a filing date is up to four business days after the thing it reports. The same feed across the whole market.
Others in SIC 2834
| Ticker | Company | Market cap | P/E | Revenue growth |
|---|---|---|---|---|
| LLY | ELI LILLY & Co | $1.20T | 55.5x | 44.7% |
| JNJ | JOHNSON & JOHNSON | $635.76B | 23.9x | 6.0% |
| ABBV | AbbVie Inc. | $504.76B | 121.0x | 8.6% |
| MRK | Merck & Co., Inc. | $358.41B | 20.0x | 1.3% |
| ABT | ABBOTT LABORATORIES | $180.63B | 27.9x | 5.7% |
| PFE | PFIZER INC | $171.16B | 22.1x | -1.6% |
| VRTX | VERTEX PHARMACEUTICALS INC / MA | $132.80B | 34.2x | 8.9% |
| BMY | BRISTOL MYERS SQUIBB CO | $125.59B | 17.8x | -0.2% |